Weary of Prior Auths? What Would Happen If You Were Paid by the Insurers to Submit Them?

Published Date: 10 May 2024

Approving a prior authorization CPT code is what the NYC urologist is requesting.

Read Full News

Latest News

Biomarker to Bedside: Practical Approaches to HER2 Testing and Targeted Treatment in Gynecologic Cancers

Biomarker to Bedside: Practical Approaches to HER2 Testing and Targeted Treatment in Gynecologic Cancers

From Pathways to Practice: Improving Outcomes for Veterans With Metastatic Hormone-Sensitive Prostate Cancer

From Pathways to Practice: Improving Outcomes for Veterans With Metastatic Hormone-Sensitive Prostate Cancer

Bladder Issues Linger in Kids Treated for Ureter Swelling

Many children surgically treated for a swelling at the end of the ureter have lasting bladder symptoms, such as holding urine or trouble passing stools.

Precision Oncology in mHSPC: Translating Emerging Evidence Into Clinical Practice

Precision Oncology in mHSPC: Translating Emerging Evidence Into Clinical Practice

Practical Implications of Targeted Therapies in mHSPC Care

Practical Implications of Targeted Therapies in mHSPC Care

Clinical Data and Expert Perspectives on Emerging Bispecific ADCs in Urothelial Carcinoma

Clinical Data and Expert Perspectives on Emerging Bispecific ADCs in Urothelial Carcinoma

Todays Updates

Trappsol Cyclo Misses Primary End Point in Phase 3 Trial for Niemann-Pick Disease Type C Isabella Ciccone, MPH

Findings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.

NeurologyLive® Friday 5 — October 2, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.

Todays Updates

Trappsol Cyclo Misses Primary End Point in Phase 3 Trial for Niemann-Pick Disease Type C Isabella Ciccone, MPH

Findings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.

NeurologyLive® Friday 5 — October 2, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.

Latest News

Biomarker to Bedside: Practical Approaches to HER2 Testing and Targeted Treatment in Gynecologic Cancers

From Pathways to Practice: Improving Outcomes for Veterans With Metastatic Hormone-Sensitive Prostate Cancer

Many children surgically treated for a swelling at the end of the ureter have lasting bladder symptoms, such as holding urine or trouble passing stools.

Precision Oncology in mHSPC: Translating Emerging Evidence Into Clinical Practice

Practical Implications of Targeted Therapies in mHSPC Care

Clinical Data and Expert Perspectives on Emerging Bispecific ADCs in Urothelial Carcinoma

News All Time

Latest Clinical Data for Emerging Combination Strategies in mHSPC

Latest Clinical Data for Emerging Combination Strategies in mHSPC

Redefining MIBC Standards: Multidisciplinary Insights on Optimizing Immunotherapy-Based Combinations

Redefining MIBC Standards: Multidisciplinary Insights on Optimizing Immunotherapy-Based Combinations

Towards Personalized Treatment in mHSPC: Latest Evidence for Biomarker-Targeted Therapies and Multidisciplinary Toxicity Management

Towards Personalized Treatment in mHSPC: Latest Evidence for Biomarker-Targeted Therapies and Multidisciplinary Toxicity Management

Shaping the Future of Muscle-Invasive Bladder Cancer Treatment With the Integration of Immunotherapy and Multidisciplinary Care

Shaping the Future of Muscle-Invasive Bladder Cancer Treatment With the Integration of Immunotherapy and Multidisciplinary Care

Advancing mHSPC Management: From Clinical Guidelines to Emerging Biomarker-Directed Therapies

Advancing mHSPC Management: From Clinical Guidelines to Emerging Biomarker-Directed Therapies

Optimizing mHSPC Care: Integrating Novel Combination Therapies and the Strategies for Multidisciplinary Management

Optimizing mHSPC Care: Integrating Novel Combination Therapies and the Strategies for Multidisciplinary Management

Personalized Decision-Making for Patients With Advanced HSPC

Personalized Decision-Making for Patients With Advanced HSPC

Too Much or Too Little Opioid Pain Relief May Drive Refills After Urologic Surgery

Discharge prescription mismatch versus inpatient dose significantly increased refill rate

Durvalumab Plus BCG Cut Early Recurrence of High-Risk Bladder Cancer

POTOMAC data support a year's worth of immuontherapy paired with BCG induction and maintenance

Half of Patients With Post-BCG Bladder Cancer Achieve CR With Nonviral Gene Therapy

Detalimogene voraplasmid lead to numerous durable complete responses with favorable safety

Low-Intensity Ultrasound Shatters Kidney Stones in 70% of SOUND Trial Patients

Non-invasive, no-anesthesia lithotripsy recently gained FDA approval

Major Complete Response Rate in Very High-Risk Bladder Cancer With Combo Treatment

Only three of 37 patients did not achieve CR at 6 months with pembrolizumab and BCG

Temporary Prostatic Urethra Expander for BPH/LUTS Shows Durable Results

Study showed immediate improvement in symptoms after intentional retrieval of device at 6 months

Evidence Mounts for Darolutamide Plus ADT in Hormone-Sensitive Prostate Cancer

U.S. study supports findings from a global trial using an external control arm

He Inserted a Cable in His Penis. 10 Years Later, He Needed Surgery.

Patient in his 60s eventually developed sepsis

Erectile Dysfunction May Predispose Older Men to Multiple Types of Substance Abuse

Significantly higher risk of sedative, opioid, cocaine abuse compared with no ED diagnosis

Recommended News For You

What are the factors that cause oral mucositis to be severe after receiving radiation for head and neck cancer?

Tissue-Free ctDNA Predicts Recurrence in Early Breast Cancer

Axatilimab Demonstrates Effectiveness in Refractory/Recurrent GVHD.

Three-Drug Regimens Make Case for a Role in Untreated and Relapsed/Refractory CLL

C/EBP? works in tandem with MYB to sustain AML cells' oncogenic program.

Hemihedral resection not necessary for neuroendocrine surgery after appendicitis

One possible target in acute myeloid leukemia is the reductive carboxylation of glutamine.

Recommended Articles For You

Lactic Acid-Linked lncRNAs in Wilms Tumor: Decoding the Tumor Microenvironment & Prognosis 

Beyond Immunotherapy: Emerging Novel Treatments for Small Cell Lung Cancer 

Iron Metabolism and Inflammatory Disorders: Mechanisms, Clinical Implications, and Therapeutic Approaches 

Rare Malignant Ovarian Tumors: A Comprehensive Review for Clinicians 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Early Identification of Ovarian Cancer; Allergy Medicine for NSCLC? Unfavorable Development for Anti-TIGIT Medication?

2.

No Laughing Matter: Nitrous Oxide for Transrectal Prostate Biopsy.

3.

Biomarker panel offers hope for early pancreatic cancer detection

4.

Financial hardship common in patients with cancer

5.

New protocols, according to a study, allow many patients to safely return home one day after lung cancer surgery.

1.

What You Need To Know About Secondary Polycythemia: Treatment & Symptoms

2.

Emerging Methods in Hematology in Clinical Decision-Making

3.

Fatigue Rehabilitation in Blood Disorders

4.

Digital Morphology Libraries for Hematology Education: Transforming Diagnostic Training and Clinical Practice

5.

Understanding Abemaciclib: A Breakthrough Treatment for Breast Cancer 

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

1.

Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias- The Summary

2.

Early Cancer Detection Saves Lives

3.

The Role of Hemoglobin in Maintaining Healthy Oxygen Levels

4.

Managing ALK+ NSCLC while Ensuring Long-Term Safety of the Patients

5.

A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot